Genexine

Overview Innovative and next-generation novel drug clinical development

Our clinical development capabilities
have acted as a compass for
bio-venture development strategies
based our experience.

Genexine’s vision of treating patients and improving their quality of life is being practically realized owing to faster and more accurate drug development based on clinical planning and execution, management of clinical trial institutions, and smooth communication with regulatory authorities.

Moreover, we play a central role in collaborating with global partners through the effective use of external resources and active exchange at scientific meetings and/or academic seminars with domestic and foreign partners and joint venture partners.
Our clinical development capabilities have acted as a compass for bio-venture development strategies based on our experience of conducting around 20 clinical trials, both rapidly and accurately, on healthy adults and patients over the past five years.

Prioritized Pipeline

Immuno-oncology
Candidate Indication Development Phase Collaborator
GX-E4 Long-acting erythropoietin
CKD-induced anemia
Preclinical Phase 1 Phase 2 Phase 3 Commercial
GX-H9 Long-acting hunman growth hormone
Pediatric & Adult growth hormone deficiency
Preclinical Phase 1 Phase 2 Phase 3 Commercial

GX-188E Therapeutic DNA Vaccine for HPV 16/18 genotype
Cervical cancer
Preclinical Phase 1 Phase 2 Phase 3 Commercial
Head & Neck cancer
Investigator-Initiated Trial (IIT)
Preclinical Phase 1 Phase 2 Phase 3 Commercial
GX-I7 Long-acting human interleukin-7
Lymphopenia, solid tumors, infectious disease
Preclinical Phase 1 Phase 2 Phase 3 Commercial


GX-G6 Long-acting GLP-1
Type 2 Diabetes / Obesity
Preclinical Phase 1 Phase 2 Phase 3 Commercial

GX-P1 Long-acting PD-L1
Autoimmune disease, Transplatation
Preclinical Phase 1 Phase 2 Phase 3 Commercial
GX-G3 Long-acting G-CSF
Neutropenia
Preclinical Phase 1 Phase 2 Phase 3 Commercial